C.R. Bard Prevails In The Fourth IVC Filter Bellwether Trial
C.R. Bard Prevails In The Fourth IVC Filter Bellwether Trial

Introduction
The fourth bellwether trial involving design defects claims brought by a couple over of the inferior vena cava filter (IVC filter) concluded with the Arizona federal jury ruling in favor of Becton Dickinson & Company’s subsidiary C.R. Bard.
The woman underwent treatment for deep-vein thrombosis and pulmonary embolism in 2011 when she was implanted with C.R. Bard’s G2X Blood vessel filter. The device was reported to be a failure, and she got it surgically removed in 2014 after suffering severe internal injuries due to the device breakage. Her case went to trial last month when the federal jury dismissed her claim that there was a possibility of a heart arrhythmia condition in the future. The case became the third bellwether trial as its predecessor case was dismissed over the late filing of the claims.
The first bellwether trial against Bard concluded with the jury awarding plaintiff Sherr-Una Booker $ 3.6 million in damages, while the second bellwether ended in a defense verdict. The manufacturer faces more than 3,800 lawsuits related to design flaws in the blood clot filters. Similar cases are consolidated as a part of a multidistrict litigation (MDL No. 2641; In Re: Bard IVC Filters Products Liability Litigation) for coordinated pretrial proceedings, overlooked by Judge David G. Campbell, in the United States District Court District of Arizona.
Latest News
Talcum Powder Cancer Settlement Talks Begin Sept. 4
Representatives of Johnson & Johnson (J&J) and attorneys for tens of thousands of plaintiffs involved in talcum powder lawsuits are scheduled to meet in September 2025 in an…
Tepezza Hearing Loss Trials Delayed Until Aug 2026
A series of Tepezza hearing loss lawsuits, which were expected to go before juries next year, will now be delayed. The U.S. District Judge overseeing the multidistrict…
Cencora Directors Settle Opioid Oversight Case for $111M
Cencora has agreed to pay $111.3 million to settle a shareholder lawsuit accusing the company’s directors of failing to prevent the unlawful distribution of opioids…